{
    "id": 13381,
    "fullName": "ABL1 L387M",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 L387M lies within the protein kinase domain of the Abl1 protein (UniProt.org). L387M has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL1 (PMID: 21562040, PMID: 28451802), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 14494,
                    "pubMedId": 28451802,
                    "title": "Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28451802"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 3828,
                    "pubMedId": 21562040,
                    "title": "BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21562040"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "L387M",
    "createDate": "10/29/2015",
    "updateDate": "10/01/2019",
    "referenceTranscriptCoordinates": {
        "id": 119196,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130874941T>A",
        "cDna": "c.1159T>A",
        "protein": "p.L387M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16825,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ABL1 L387M in the context of BCR-ABL1 was identified in a BCR-ABL1-positive chronic myeloid leukemia patient who demonstrated resistance to Gleevec (imatinib) treatment (PMID: 24456693).",
            "molecularProfile": {
                "id": 23538,
                "profileName": "BCR - ABL1 ABL1 L387M"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5511,
                    "pubMedId": 24456693,
                    "title": "BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24456693"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20989,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing ABL1 L387M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 23538,
                "profileName": "BCR - ABL1 ABL1 L387M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20940,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited survival of transformed cells expressing both ABL1 T315I and ABL1 L387M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35456,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 L387M"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20953,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ABL1 L387M and T315I in the context of BCR-ABL1 were resistant to Iclusig (ponatinib) in cell culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35456,
                "profileName": "BCR - ABL1 ABL1 T315I ABL1 L387M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20961,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 F317L and L387M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35462,
                "profileName": "BCR - ABL1 ABL1 F317L ABL1 L387M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20975,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited survival of transformed cells expressing both ABL1 V299L and L387M in the context of BCR-ABL1 in culture (PMID: 28983061).",
            "molecularProfile": {
                "id": 35467,
                "profileName": "BCR - ABL1 ABL1 V299L ABL1 L387M"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18128,
                    "pubMedId": 28983061,
                    "title": "BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28983061"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13567,
            "profileName": "ABL1 L387M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23538,
            "profileName": "BCR - ABL1 ABL1 L387M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35456,
            "profileName": "BCR - ABL1 ABL1 T315I ABL1 L387M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35462,
            "profileName": "BCR - ABL1 ABL1 F317L ABL1 L387M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35467,
            "profileName": "BCR - ABL1 ABL1 V299L ABL1 L387M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119196,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130874941T>A",
            "cDna": "c.1159T>A",
            "protein": "p.L387M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}